Media stories about Ritter Pharmaceuticals (NASDAQ:RTTR) have trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 47.348769105699 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Ritter Pharmaceuticals (NASDAQ:RTTR) traded down $0.03 on Tuesday, reaching $0.31. 1,457,079 shares of the company’s stock traded hands, compared to its average volume of 1,820,000. Ritter Pharmaceuticals has a 12 month low of $0.29 and a 12 month high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14). sell-side analysts anticipate that Ritter Pharmaceuticals will post -0.66 EPS for the current year.

Several research firms have recently commented on RTTR. Zacks Investment Research cut shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Roth Capital set a $2.00 price target on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Chardan Capital decreased their price target on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a research note on Tuesday, August 8th. HC Wainwright decreased their price target on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a research note on Monday, October 23rd. Finally, Maxim Group reaffirmed a “hold” rating on shares of Ritter Pharmaceuticals in a research note on Friday, August 4th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $2.92.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Ritter Pharmaceuticals (RTTR) Share Price” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-ritter-pharmaceuticals-rttr-share-price/1686430.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Insider Buying and Selling by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.